TY - JOUR
T1 - Clinicopathologic features and treatment outcome of primary breast diffuse large B-cell lymphoma
AU - Niitsu, Nozomi
AU - Okamoto, Masataka
AU - Nakamine, Hirokazu
AU - Hirano, Masami
N1 - Funding Information:
The authors thank for having had Dr. S. Nakamura, Dr. Oshima, Dr. Tamaru, Dr. N. Nakamura and Dr. Yoshino performing pathological diagnosis. Supported in part by a grant from the Ministry of Health and Welfare, and Grants-in-Aid for Scientific Research (C) and Cancer Research, from The Ministry of Education, Culture, Sports, Science, and Technology (MEXT) Japan.
PY - 2008/12
Y1 - 2008/12
N2 - We studied the clinicopathologic features and treatment outcome of patients with breast diffuse large B-cell lymphoma. As to the cellular immunophenotype, CD5 was detected in two patients, CD10 in 4, BCL2 in 20, BCL6 in 11, and MUM-1 in 17. The 5-year progression-free survival was 77% and the 5-year overall survival was 87%. Patients with the germinal center B-cell (GCB) type had a significantly better prognosis than those with the non-GCB type. The combination of anthracycline-containing chemotherapy and/or involved-field radiotherapy produced a relatively good prognosis. However, it is a heterogeneous disease with regard to histological type and pathological state.
AB - We studied the clinicopathologic features and treatment outcome of patients with breast diffuse large B-cell lymphoma. As to the cellular immunophenotype, CD5 was detected in two patients, CD10 in 4, BCL2 in 20, BCL6 in 11, and MUM-1 in 17. The 5-year progression-free survival was 77% and the 5-year overall survival was 87%. Patients with the germinal center B-cell (GCB) type had a significantly better prognosis than those with the non-GCB type. The combination of anthracycline-containing chemotherapy and/or involved-field radiotherapy produced a relatively good prognosis. However, it is a heterogeneous disease with regard to histological type and pathological state.
UR - http://www.scopus.com/inward/record.url?scp=51649089821&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=51649089821&partnerID=8YFLogxK
U2 - 10.1016/j.leukres.2008.04.005
DO - 10.1016/j.leukres.2008.04.005
M3 - Article
C2 - 18490056
AN - SCOPUS:51649089821
VL - 32
SP - 1837
EP - 1841
JO - Leukemia Research
JF - Leukemia Research
SN - 0145-2126
IS - 12
ER -